Short Interest in Trevena, Inc. (NASDAQ:TRVN) Grows By 59.4%

Trevena, Inc. (NASDAQ:TRVN) was the target of a large increase in short interest in July. As of July 31st, there was short interest totaling 5,100 shares, anincreaseof59.4% from the July 15th total of 3,200 shares. Based on an average trading volume of 700 shares, the short-interest ratio is currently 7.3 days. Approximately0.6% of the company’s stock are sold short. Approximately0.6% of the company’s stock are sold short. Based on an average trading volume of 700 shares, the short-interest ratio is currently 7.3 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen initiated coverage on Trevena in a research note on Thursday, May 22nd. They set a “sell” rating on the stock.

Trevena Price Performance

NASDAQ TRVN opened at $0.28 on Monday. The stock has a market capitalization of $268,520.00, a price-to-earnings ratio of -0.01 and a beta of 0.41. Trevena has a one year low of $0.25 and a one year high of $7.85. The business’s fifty day moving average is $0.85 and its 200-day moving average is $1.18.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.